Skip to content
Search

Latest Stories

Thousands of breast cancer patients to benefit as NHS marks 100th fast-tracked drug

Up to 3,000 people a year with a certain type of secondary breast cancer will benefit from the treatment, which is the 100th cancer drug being fast-tracked to patients under the NHS Cancer Drugs Fund.

Thousands of breast cancer patients to benefit as NHS marks 100th fast-tracked drug

THOUSANDS of people a year with advanced breast cancer will benefit from a life-extending drug that has been fast-tracked onto the frontline of NHS patient care.

The drug, alpelisib, will be used in combination with the hormone therapy, fulvestrant, to target the gene that causes fast-growing tumours.


Up to 3,000 people a year with a certain type of secondary breast cancer will benefit from the treatment, which is the 100th cancer drug being fast-tracked to patients under the NHS (National Health Service) Cancer Drugs Fund (CDF), with 80,000 benefitting from a CDF drug in just over five years.

The £340-million funding pot for new cutting-edge cancer drugs allows the NHS to make the drugs available to patients months earlier than was previously possible, while further data is collected by the manufacturer and then used by NICE to support their final recommendations for use on the NHS.

The approach has contributed to people in England having access to nearly one third more cancer drugs compared to the European average.

The drug combination works by blocking the rogue gene’s ability to help cancer cells to survive and grow, with a key study showing that in half of people who received alpelisib with fulvestrant after previous treatment, their cancer did not progress for six months

The treatment, which is manufactured by pharmaceutical company Novartis, is part of a growing number of precision treatments that target a tumour based on mutations in its DNA and that the NHS is rolling out.

John Stewart, NHS national director for specialised commissioning said, “In just over five years, more than 80,000 people have benefitted from earlier access to a range of cancer drugs, with people in England having access to nearly one third more cancer drugs compared to the European average, and this latest innovative new treatment will help up to 3,000 more to live a better quality of life.

“This life-extending breast cancer treatment is the 100th to be rapidly made available to NHS patients thanks to the Cancer Drugs Fund, and will help people with secondary breast cancer to live longer.”

Before prescribing the drug, clinicians will take a small amount of tissue from a patient’s tumour and send it to a NHS Genomic Laboratory Hub for a new genomic test that can identify and then treat the tumour, if appropriate.

If this new test, which is now part of the National Genetic Testing Directory, shows a mutation in the specific gene called PIK3CA, then the targeted treatment could be offered to those who have not responded to other treatments.

A blood test could also be used to demonstrate circulating tumour DNA which can also show the specific mutation causing the cancer.

Breast-cancer patients that have received prior treatment with an endocrine and CDK4/6 inhibitor will be able to benefit from this treatment on the NHS after the medicines regulator, the MHRA, extended the license for the treatment in December 2021.

Professor Dame Sue Hill, chief scientific officer for England and the senior responsible officer for NHS Genomics said, “This is another powerful example of how genomic testing is supporting access to precision medicine for individuals living with cancer and allowing them to access more effective treatments on the NHS.

“Genomics is helping to revolutionise cancer care and the NHS Genomic Medicine Service is leading the way in delivering the latest genomic technologies to deliver better outcomes for patients.”

The NHS Long Term Plan is committed to providing the latest cutting-edge treatments and therapies for patients, and the CDF provides faster access to promising cancer treatments on the health service in England.

Along with the existing £340 million CDF, the NHS launched in June a new £340m Innovative Medicines Fund, meaning a total of £680 million of ringfenced NHS England funding will be available to deploy on fast-tracked cancer and non-cancer drugs.

Health and social caresecretary Steve Barclay said, “These new drugs will benefit over 1,000 cancer patients across the country, offering them more precious moments with their loved ones and a better quality of life.

“We are constantly monitoring the most promising treatments. The incredible work of the Cancer Drugs Fund has now provided early access to 100 cancer treatments for more than 80,000 patients since 2016 and is a pioneer for innovation.”

Baroness Delyth Morgan, chief executive at Breast Cancer Now, said, “It’s absolutely fantastic news that following a provisional rejection in March, alpelisib with fulvestrant has now been recommended by NICE for routine use on the NHS, bringing hope to thousands of patients living with a particular type of incurable secondary breast cancer.

“This will be the first targeted treatment option available for certain patients with a PIK3CA mutation which is estimated to be found in around 30-40 per cent of oestrogen receptor positive, HER2 negative breast cancers. Importantly, clinical evidence suggests that alpelisib with fulvestrant is more effective than the current standard treatment option – everolimus with exemestane – and is another step in delaying chemotherapy for patients, which can be associated with grueling side effects.”

Marie-Andrée Gamache, country president, Novartis Innovative Medicines UK and Ireland, said, “We know an advanced breast cancer diagnosis is devastating for patients and their loved ones, so we’re delighted that alpelisib has been approved as a treatment via the NHS in England and Wales.

“As part of our ongoing commitment to the breast cancer community, we have secured a broader licence with the MHRA and worked closely with NICE on this appraisal to provide access to as many eligible patients as quickly as possible. We welcome the systems in place to make alpelisib available immediately through interim funding from the Cancer Drugs Fund, and will continue to partner with the NHS and the entire healthcare system to identify new innovations that improve the quality of life for people with cancer.”

More For You

Minouche Shafik

Shafik served as deputy governor for markets and banking at the Bank of England between August 2014 and February 2017.

Reuters

Starmer appoints Minouche Shafik as chief economic adviser in reshuffle

Highlights:

  • Minouche Shafik named chief economic adviser to Keir Starmer.
  • Darren Jones moves into Downing Street role; James Murray replaces him.
  • Wider reshuffle includes changes in Starmer’s private office and communications.
  • Appointment comes ahead of a budget expected to include further tax rises.

Prime minister Keir Starmer has named Minouche Shafik, a former deputy governor of the Bank of England, as his chief economic adviser. The appointment comes as he looks to strengthen his team ahead of what is expected to be a difficult end to the year.

Keep ReadingShow less
modi putin

Before their formal meeting, Putin offered Modi a ride in his Aurus limousine.

X/@narendramodi

Six key takeaways from the SCO summit

INDIAN prime minister Narendra Modi met Russian president Vladimir Putin and Chinese president Xi Jinping on the sidelines of the Shanghai Cooperation Organisation (SCO) summit in Tianjin, China.

Modi pressed for ending the Ukraine conflict at the earliest, reaffirmed India’s long-standing ties with Russia, and discussed trade and border issues with Xi.

Keep ReadingShow less
Afghanistan earthquake

Afghan volunteers and Taliban security personnel carry an earthquake victim evacuated by a military helicopter from the Nurgal district of Kunar province onn September 1, 2025.

Getty Images

Afghanistan earthquake kills more than 800, thousands injured

A MAJOR rescue operation was underway in Afghanistan on Monday after a powerful earthquake and several aftershocks destroyed homes in a remote mountainous region, killing more than 800 people, according to Taliban authorities.

The quake struck just before midnight and was felt as far as Kabul and in Pakistan’s capital, Islamabad.

Keep ReadingShow less
Ganpati festival

The Ganpati festival celebrates Ganesha as the god of new beginnings, and the god of wisdom and intelligence. (Photo: Getty Images)

Getty Images

Hindu community centre in London damaged in fire after Ganapati Visarjan event

A HINDU community centre in east London caught fire on Saturday evening, causing major damage to the building. The London Fire Brigade brought the fire under control and confirmed that no injuries were reported.

The incident took place at the Shree Sorathia Prajapati Community Centre on Cleveland Road in Ilford, which had been decorated for a Ganapati Visarjan event attended by members of the Hindu community.

Keep ReadingShow less
Modi ,Xi & Putin

Narendra Modi talks with Vladimir Putin and Xi jinping ahead of the Shanghai Cooperation Organization (SCO) Summit 2025 at the Meijiang Convention and Exhibition Centre in Tianjin on September 1, 2025.

Getty Images

SCO declaration slams Pahalgam attack, calls for united action on terror

Highlights:

  • SCO condemns terror attack in Pahalgam and echoes India’s stance on “double standards”.
  • Leaders call for justice for perpetrators of attacks in Pahalgam and Balochistan.
  • Declaration criticises Israeli military strikes in Gaza causing civilian casualties.
  • SCO stresses UN’s central role in global counter-terrorism strategy.

THE SHANGHAI Cooperation Organisation (SCO) on Monday condemned the terror attack in Pahalgam and agreed with India’s position that “double standards” in tackling terrorism are not acceptable.

Keep ReadingShow less